AUTHORS
Foteini Theodorakakou, MD, Ioannis V Kostopoulos, PhD, MSc2, Eirini Solia, MD3, Nikolaos Kanellias, MD, PhD4, Alexandra Papadimou5, Konstantina Taouxi6, Katerina Chrisostomidou7, Ilias Katsadouros, MD8, Panagiotis Boutsikos, MD9, Ioannis Ntanasis-Stathopoulos, MD10, Panagiotis Malandrakis, MD, MSc, PhD11, Evangelos Eleutherakis-Papaiakovou12, Angeliki Alifragki13, Asimina Papanikolaou14, Maria Gavriatopoulou, MD15, Evangelos Terpos, MD16, Ourania Tsitsilonis, MD,PhD17, Meletios-Athanasios (Thanos) C. Dimopoulos, MD18, Efstathios Kastritis, MD19
AFFILIATIONS
1 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
2 National and Kapodistrian University of Athens, Athens, Greece
3 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
4 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
5 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
6 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
7 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
8 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
9 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
10 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
11 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
12 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
13 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
14 Department of Haematopathology, Evangelismos Hospital, Athens, Athens, Greece
15 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
16 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
17 National and Kapodistrian University of Athens, Athens, Greece
18 Korea University, Seoul, South Korea, Seoul, Korea, Rep. of South, National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
19 National and Kapodistrian University of Athens, School of Medicine, Athens, Greece
ABSTRACT
In AL amyloidosis, daratumumab induces deep hematologic responses that translate to higher rates of organ responses and improved survival. Undetectable minimal residual disease (MRD) has been associated with lower probability of hematologic relapse and higher probability of organ responses, but its role in the daratumumab era has not been validated.
In order to evaluate the prognostic role of MRD, we analyzed the data of 87 patients who have received upfront therapy with daratumumab, had achieved hemCR or hemVGPR (within 6 months from treatment initiation) and were evaluated for MRD using next generation flow cytometry (NGF) (According to Euroflow protocols, with a sensitivity of 2x10-6), at 6 and/or 12 months.
At diagnosis, 44% were female and median age was 62 years. Distribution per Mayo stage 1, 2, 3a and 3b was 15%, 46%, 22% and 17%, respectively; 59% had renal, 80.5% cardiac, 32% liver, 23% nerve and 29% soft tissue involvement. Median eGFR was 79.4 ml/min/1.73m2, proteinuria was 3000 mg/24h and median GLS was -14%. Median BMPC infiltration was 15% and iFLC 297 mg/L; 52% had t(11;14) and 22% gain or amplification of 1q21. The hematologic response at the time of MRD evaluation was hemCR in 68 and hemVGPR in 19 patients. Among hemCR patients, 60 (88%) had lambda and 8 (12%) kappa isotype while among hemVGPR 11 (58%) had lambda and 8 (42%) kappa, respectively. At 6- and 12-month landmarks, 75/87 and 82/87 patients were assessed for MRD; 27/75 (31%) and 29/82 (33%) were MRD negative (MRDneg); none of hemVGPR patients achieved MRD negativity. Among 43 patients that were tested as MRDpos at 6 months, only one converted to MRDneg in subsequent evaluations, while among 29 that were tested as MRDneg at 6 months, 2 patients converted MRDpos at 12 months, both at the level of detection (10-6).
Patients who were MRDneg at either the 6- or 12- month landmark, had more frequent renal involvement (74% vs 50% for MRDpos, p=0.040) while there were no significant differences in baseline Mayo stage or degree of clonal burden between MRDneg and MRDpos patients. Notably, patients with lambda isotype achieved higher rates of MRD negativity; 42% of lambda patients were MRDneg vs only 6% of kappa, p=0.008), and this difference remained significant when we focused the analysis only on patients with hemCR (50% of lambda patients were MRDneg vs 12.5% of kappa [p=0.046]).
At 6-month landmark, among evaluable patients (n=54), cardiac response was observed in 64% of MRDneg vs 68% of MRDpos patients (p=0.772), while CarCR/VGPR in 31% vs 34% (p=0.859), respectively. At 12-month landmark among evaluable patients (n=56), cardiac response was observed in 76% vs 77% (p=0.783), while CarCR/VGPR in 45.5% vs 46.5% (p=0.922), respectively. Among evaluable patients with renal involvement, at 6-month landmark (n=37) renal response was observed in 57% of MRDneg vs 43% of MRDpos (p=0.371), and at 12-month landmark (n=44), in 58% vs 56.5% (p=0.569), respectively.
Median follow-up was 41 months and median overall survival (OS) has not been reached; 4-year OS was 93% and there was no significant difference according to MRD status at either landmark. At 6-month landmark, among the whole cohort, 4-year event free survival (EFS) rate for MRDneg was 100% vs 77% of MRDpos (p=0.038) and among patients with hemCR was 100% vs 85% (p=0.299). At 12-month, among the whole cohort 4-year EFS rate for MRDneg was 100% vs 78% (p=0.029) and among patients with hemCR, 100% vs 86% (p=0.072). Among those MRDneg at 12-month landmark, none of the 29 patients required further treatment vs 12/56 MRDpos (p=0.023), and among hemCR patients, 0/29 vs 5/31 had relapsed from CR (p=0.060), respectively.
In conclusion, we confirmed that attainment of early and sustained MRD negativity is associated with prolonged OS and very low probability of requiring further treatment, among newly diagnosed AL amyloidosis patients treated with daratumumab-based therapies. Interestingly, patients with kappa light chain achieved less frequently MRD negativity, which highlight that this subgroup of patients may have distinct clinical and biological features. Notably, continuing treatment with daratumumab beyond 6 months did not seem to improve MRD negativity rates.
DISCLOSURES
Foteini Theodorakakou, MD: No relevant conflicts of interest to declare.